Most peptides in the growth-hormone corner of the catalog do not contain growth hormone. They are secretagogues — molecules that prompt the body's own pituitary to release the growth hormone it already makes. Understanding how that release is wired explains why these compounds come in two distinct families, why they are often paired, and why the body's response arrives in bursts rather than a steady stream.
This is a mechanism explainer, not a protocol. The goal is to make the GH secretagogue axis legible: the receptors involved, the brake that opposes them, and the downstream signal that ultimately does most of the measurable work.
The Axis in One Picture
Growth hormone (GH) release from the anterior pituitary is governed by a small committee of upstream signals. Three of them matter most:
- GHRH (growth-hormone-releasing hormone) — a hypothalamic peptide that says release.
- Ghrelin — a stomach-derived peptide that also says release, through a completely different receptor.
- Somatostatin — the hypothalamic brake that says stop.
These signals converge on the somatotrophs, the GH-producing cells of the pituitary. The amount of GH that leaves the pituitary at any moment is essentially the net result of two accelerators and one brake. Once GH enters circulation, it travels to the liver and peripheral tissues and drives production of IGF-1 (insulin-like growth factor 1), which mediates many of GH's longer-acting effects and also feeds back to suppress the axis.
That feedback loop is the reason the system behaves the way it does — and the reason secretagogues are studied as a way to work with the loop rather than overriding it.
Receptor One: The GHRH Receptor
The first accelerator is the GHRH receptor (GHRH-R), a G-protein-coupled receptor on the somatotroph surface. When GHRH binds, it raises intracellular cyclic AMP, which both promotes GH synthesis and primes the cell to release it.
Several catalog compounds are studied as GHRH analogs — research molecules built to engage this receptor like native GHRH but with modified pharmacokinetics:
- Sermorelin corresponds to the first 29 amino acids of GHRH (GHRH 1-29), the minimal fragment that retains activity.
- CJC-1295 No-DAC and CJC-1295 DAC are GHRH 1-29 analogs with stabilizing substitutions; the DAC ("Drug Affinity Complex") version adds a moiety that binds albumin to extend its presence in circulation.
- Tesamorelin is a stabilized GHRH analog that has been studied most extensively in the context of visceral adipose tissue in research literature.
What unites this family is the receptor they target. They are, in effect, longer-lived versions of the body's own release signal. Because they act through the physiological GHRH pathway, the somatotroph's own machinery — and the somatostatin brake — still shapes the output.
Receptor Two: The Ghrelin Receptor (GHS-R)
The second accelerator is the growth-hormone secretagogue receptor (GHS-R), better known as the ghrelin receptor. This is a separate GPCR that signals primarily through a different intracellular cascade (phospholipase C and intracellular calcium). Its natural ligand is ghrelin, the "hunger hormone," but a large class of synthetic peptides — the growth-hormone-releasing peptides (GHRPs) — were developed to engage it.
Catalog compounds in this family include:
- Ipamorelin — studied for relatively selective GHS-R activation with comparatively little effect on other pituitary hormones in preclinical work.
- GHRP-2 and GHRP-6 — earlier-generation secretagogues; GHRP-6 is noted in the literature for a stronger appetite signal, consistent with the ghrelin receptor's role.
- Hexarelin — a potent GHS-R agonist studied in cardiovascular as well as GH-release contexts.
The ghrelin receptor does something the GHRH receptor does not: in research models, GHS-R activation also transiently suppresses somatostatin tone. In plain terms, this arm of the axis doesn't only press the accelerator — it briefly eases off the brake.
Why GHRH and Ghrelin Analogs Are Studied Together
This is the crux of the whole system. The two receptors are synergistic, not redundant.
When a GHRH analog and a GHS-R agonist are present at the same time, the literature describes a GH release larger than the sum of either alone. The mechanistic story is intuitive once the wiring is clear:
- The GHRH arm primes and pushes the somatotroph to release GH.
- The ghrelin arm pushes through a second, independent pathway and lifts the somatostatin brake.
Pressing two different accelerators while releasing the brake produces a coordinated pulse. This is the rationale behind blended research compounds such as the CJC-1295 + Ipamorelin Blend — one molecule per receptor arm. The pairing is a direct expression of the two-receptor architecture, not a marketing convenience.
The Somatostatin Brake and Why Pulses Matter
Healthy GH secretion is pulsatile. Levels are low most of the day and spike in bursts, the largest typically tied to slow-wave sleep. Somatostatin is what carves those valleys: when somatostatin tone is high, even a strong release signal produces little GH.
This matters for interpreting any secretagogue. Because these compounds act upstream of GH itself, their output is gated by the prevailing somatostatin rhythm. A release signal arriving during a somatostatin trough produces a much larger pulse than the same signal arriving during a peak. The axis, in other words, has its own timing — and secretagogues are studied as ways to amplify a pulse, not to flatten the rhythm into a plateau.
Preserving pulsatility is one of the conceptual distinctions researchers draw between secretagogues and exogenous GH itself, such as HGH 191AA. Administered GH raises circulating levels directly and bypasses the pituitary's release machinery entirely; a secretagogue works through it. The two approaches engage the axis at completely different points.
Downstream: IGF-1 and Negative Feedback
GH's effects are partly direct and partly delegated. A large share is mediated by IGF-1, produced mainly by the liver in response to GH. IGF-1 is the longer-acting signal, and much of what the literature measures downstream of GH is really IGF-1 activity. The catalog's IGF-1 LR3 is a research analog of this downstream messenger itself, engaging the system one step below GH.
IGF-1 also closes the loop. Rising IGF-1 and GH feed back to the hypothalamus and pituitary to increase somatostatin and dampen further release. This negative feedback is the axis's built-in governor — the reason the system tends toward a setpoint and resists indefinite escalation. Any honest account of secretagogue pharmacology has to include this brake, because it is precisely what keeps the upstream and downstream arms in conversation.
Frequently Asked Questions
Are GHRPs and GHRH analogs the same thing? No. They target two different receptors. GHRH analogs (sermorelin, CJC-1295, tesamorelin) act on the GHRH receptor; GHRPs and related secretagogues (ipamorelin, GHRP-2/6, hexarelin) act on the ghrelin receptor, GHS-R. The distinction is the foundation of the whole axis.
Why are the two classes blended in research compounds? Because the receptors are synergistic. One arm presses the GHRH accelerator; the other presses a second accelerator and eases the somatostatin brake. Together they produce a larger, more coordinated GH pulse in preclinical models than either alone.
How is a secretagogue different from growth hormone itself? A secretagogue prompts the pituitary to release its own GH and is gated by the body's feedback and pulsatility. Exogenous GH raises circulating levels directly, bypassing that machinery. They act at different points in the same axis.
For more on how these compounds are characterized and verified before they reach a research setting, see our quality overview, or browse the full library.
This article is educational and for the laboratory research community. Trulogic Labs products are sold for laboratory and research use only and are not for human consumption.